跳至主要内容
临床试验/EUCTR2021-001624-17-SE
EUCTR2021-001624-17-SE进行中(未招募)1 期

Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Progesterone Breast Endometrial Safety study)

Karolinska University Hospital0 个研究点目标入组 520 人开始时间: 2021年6月14日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
520

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - Healthy and naturally postmenopausal women (more than one year since last menstruation or FSH > 40 IE/L)
  • with climacteric symptoms (sweating, hot flush and sleep problems) that adversely affect quality of life.
  • - Age 45-60 years
  • - BMI > 19 kg/m2 and = 32 kg/m2
  • - Intact uterus
  • - In case of previous MHT use, washout 8 weeks for oral MHT and 4 weeks for transdermal MHT or local
  • estrogen treatment before screening
  • - Written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 520
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Previous history of breast cancer or abnormal mammogram at baseline as assessed clinically by a radiology
  • - Previous history of endometrial cancer or hyperplasia or abnormal/proliferative endometrial biopsy at
  • - Vaginal bleeding
  • - Any concomitant medical treatment except for well-controlled hypertension, non-insulin treated type 2
  • diabetes, asthma and hypothyroidism
  • - History or presence of cardiovascular disease including thromboembolic disorder or cerebrovascular disease
  • - History or presence of liver disease, familial hyperlipidemia, epilepsy or classical migraine with aura
  • - History or presence of clinically significant depression or other psychiatric disorder that might in anyway
  • compromise the performance of the trial or undermine its scientific validity
  • - Current use of MHT or local estrogen treatment
  • - Alcohol and/or drug abuse
  • - Clinically significant findings on physical and/or gynecological examination at baseline
  • - Hypersensitivity to any of the study treatments

研究者

发起方
Karolinska University Hospital

相似试验